ReutersReuters

Takeda Pharmaceutical - Positive Results From Two Pivotal Phase 3 Studies Of Oveporexton (Tak-861) In Narcolepsy Type 1

RefinitivBacaan kurang dari 1 minit

Takeda Pharmaceutical Co Ltd 4502:

  • ANNOUNCES POSITIVE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF OVEPOREXTON (TAK-861) IN NARCOLEPSY TYPE 1

Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini